QIBA fMRI Biomarker Committee (BC) Call

Wednesday, June 3, 2020 at 11 a.m. (CT) Call Summary

In attendance

Feroze Mohamed, PhD (Co-chair)

David Soltysik, PhD (Co-chair)

Mai-Lan Ho, MD

RSNA staff

Nancy Obuchowski, PhD

Joe Koudelik

Yuxiang Zhou, PhD, DABR

Julie Lisiecki

Review of Previous Call Summary

The 05.20.2020 call summary was approved as presented

Update:

- Comments for the motor-mapping Profile have been addressed, and it was decided that there was insufficient enthusiasm to pursue technical confirmation
- Instead, the group decided to pivot from motor-mapping (v1.0) to a language-mapping (v2.0) Profile using the motor-mapping Profile as a template to fast-track Profile drafting
- There is also an effort to obtain software that may aid with technical confirmation for both Profiles

Language Profile (v2.0):

- Dr. Liu noted that more data are needed, and the BC should continue searching the literature for papers on localization
 - More information is needed for laterality approaches and reproducibility
 - No one on the call had any data on language fMRI to explore the language laterality index
 - o Dr. Mohamed suggested that the group ask Dr. Voyvodic about his data on the next call

Factors to keep in mind:

- With post-processing for language fMRI, ROI location may be challenging with additional areas
 - Need to specify which clusters will be reviewed
 - Localization data is the most important
- Need to acquire more data to add to the clinical case inclusive of both clinical and normative fMRI data
 - Dr. Obuchowski suggested that at least 30 subjects (and 30 controls) would be needed for a power analysis
- The study would need to be done twice and would likely require a total of 120 session scans
 - o The group thought this study could potentially be completed in a year
 - A multi-site study with different scanner platforms was recommended to obtain better reproducibility data
 - Dr. Liu has access to GE and Siemens platforms, though he primarily uses the GE 150
 - Dr. Ikuta has access to Siemens with DynaSuite Neuro, though he noted that this lacks a laterality index
 - Obtaining right-hemisphere dominant data will be difficult, as it is rare (<5% of population)

- Dr. Obuchowski suggested that the average within-subject coefficient of variation (wCV) for a representative sample would be sufficient
 - A random sample of 30 patients across 5-10 sites would be acceptable (wCV from each site would be very informative)
 - Another suggestion was to have 30 sites with at least one case each, though that would be more challenging
- A joint grant proposal was suggested to obtain additional data
 - o Drs. Mohamed and Liu to initiate this effort but would like someone else to be the lead point person
 - An RO3 grant was suggested as a promising mechanism
- Dr. Voyvodic was primarily testing AMPLE data previously but the group wondered if he might be able to use this data to investigate laterality as well

Action items:

- Drs. Mohamed and Liu to begin initial RO3 grant investigation
- Dr. Mohamed to follow up with Dr. Voyvodic regarding data availability for laterality studies

Next call: Wednesday, June 17, 2020 at 11 a.m. CT (1st & 3rd weeks of each month)

RSNA Staff attempt to identify and capture all committee members participating on WebEx calls. However, **if multiple callers join simultaneously or call in without logging on to the WebEx, identification is not possible.** Call participants are welcome to contact RSNA staff at QIBA@RSNA.org if their attendance is not reflected on the call summaries.